Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details) (USD $)	3 Months Ended				9 Months Ended
	Jun. 28, 2013		Jun. 29, 2012		Jun. 28, 2013		Jun. 29, 2012
Net sales	$ 570,000,000		$ 516,300,000		$ 1,659,300,000		$ 1,543,100,000
Operating income	(600,000)		59,400,000		89,700,000		187,000,000
Intangible asset amortization	(8,900,000)		(6,800,000)		(26,600,000)		(20,300,000)
Restructuring and related charges, net	(12,100,000)		(6,400,000)		(20,000,000)		(17,300,000)
Separation costs	(44,200,000)		(7,200,000)		(70,600,000)		(17,400,000)
Restructuring related accelerated depreciation	800,000		1,400,000		2,100,000		6,800,000
Specialty Pharmaceuticals
Restructuring and related charges, net	(7,000,000)		(2,300,000)		(13,600,000)		(10,200,000)
Global Medical Imaging
Restructuring and related charges, net	(5,100,000)		(4,100,000)		(6,400,000)		(7,100,000)
Operating Segments
Net sales	556,500,000	[1]	501,400,000	[1]	1,619,900,000	[1]	1,500,300,000	[1]
Operating income	108,300,000		100,200,000		316,300,000		289,000,000
Operating Segments | Specialty Pharmaceuticals
Net sales	308,600,000		254,700,000		913,200,000		746,300,000
Operating income	94,800,000		50,900,000		234,800,000		128,300,000
Operating Segments | Global Medical Imaging
Net sales	247,900,000		246,700,000		706,700,000		754,000,000
Operating income	13,500,000		49,300,000		81,500,000		160,700,000
Related Party
Net sales	13,500,000	[2]	14,900,000	[2]	39,400,000	[2]	42,800,000	[2]
Corporate, Non-Segment
Corporate and allocated expenses	(43,700,000)	[3]	(20,400,000)	[3]	(109,400,000)	[3]	(47,000,000)	[3]
Intangible asset amortization	(8,900,000)		(6,800,000)		(26,600,000)		(20,300,000)
Restructuring and related charges, net	(12,100,000)	[4]	(6,400,000)	[4]	(20,000,000)	[4]	(17,300,000)	[4]
Separation costs	(44,200,000)		(7,200,000)		(70,600,000)		(17,400,000)
Intersegment Eliminations
Net sales	$ 0		$ 0		$ 0		$ 0

[1] Amounts represent sales to external customers. There were no intersegment sales.

[2] Represents products that were sold to Covidien, which is discussed in note 11.

[3] Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.

[4] Includes restructuring-related accelerated depreciation of $0.8 million and $1.4 million for the three months ended June 28, 2013 and June 29, 2012, respectively, and $2.1 million and $6.8 million for the nine months ended June 28, 2013 and June 29, 2012, respectively.